Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boston Scientific, CryoCor sign atrial fibrillation deal

Executive Summary

Just three days after announcing it would buy Remon Medical Technologies, Boston Scientific now says it will co-develop cryoablation treatments for cardiac arrhythmia (CA) with CryoCor (minimally invasive cardiovascular devices). The companies will first focus on atrial fibrillation (Afib), the most common form of CA that affects about 6 million people worldwide and costs $9bn each year to treat US patients with the condition.
Deal Industry
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Contract

Related Companies